Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMG1 | Q96Q15 | 6/20 | 0.50 |
| ▸ | CDK1 | P06493 | 6/20 | 0.46 |
| ▸ | MTOR | P42345 | 5/20 | 0.46 |
| ▸ | CDK2 | P24941 | 5/20 | 0.46 |
| ▸ | JAK2 | O60674 | 2/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | IKBKB | O14920 | 4/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.42 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | CHUK | O15111 | 1/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.41 |
| ▸ | CDK9 | P50750 | 3/20 | 0.41 |
| ▸ | CDK7 | P50613 | 2/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1633022 | 0.89 | MAPK10 (0.44) | SMG1CDK1MTORJAK2BRD4 | |
| SCHEMBL1631108 | 0.85 | SMG1 (0.70) | SMG1CDK1MTORCDK2JAK2 | |
| SCHEMBL1632085 | 0.85 | SMG1 (0.62) | SMG1CDK1MTORCDK2JAK2 | |
| SCHEMBL12724192 | 0.84 | SMG1 (0.54) | SMG1CDK1MTORCDK2JAK2 | |
| SCHEMBL1632740 | 0.80 | CYP11B2 (0.42) | CDK1CDK2JAK2BRD4IKBKB | |
| SCHEMBL1632843 | 0.80 | IKBKB (0.42) | SMG1CDK1MTORCDK2JAK2 | |
| SCHEMBL1632747 | 0.80 | CA1 (0.41) | SMG1CDK1MTORCDK2JAK2 | |
| SCHEMBL1632821 | 0.79 | MTOR (0.49) | SMG1CDK1MTORCDK2JAK2 | |
| SCHEMBL1632522 | 0.78 | DKK1 (0.51) | CDK1CDK2IKBKBCCNT1CDK9 | |
| SCHEMBL1631949 | 0.78 | DKK1 (0.50) | CDK1CDK2IKBKBAURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | SMG1 1001/4885CDK1 83/4885MTOR 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.